BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25679062)

  • 21. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
    Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
    Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
    Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
    Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
    Beca F; Krings G; Chen YY; Hosfield EM; Vohra P; Sibley RK; Troxell ML; West RB; Allison KH; Bean GR
    Mod Pathol; 2020 Aug; 33(8):1518-1526. PubMed ID: 32123305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges.
    Tang F; Wei B; Tian Z; Gilcrease MZ; Huo L; Albarracin CT; Resetkova E; Zhang H; Sahin A; Chen J; Bu H; Abraham S; Wu Y
    Histopathology; 2011 Jul; 59(1):106-15. PubMed ID: 21668471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
    Lavigne M; Menet E; Tille JC; Lae M; Fuhrmann L; Bonneau C; Deniziaut G; Melaabi S; Ng CCK; Marchiò C; Rouzier R; Bièche I; Vincent-Salomon A
    Mod Pathol; 2018 Jan; 31(1):68-82. PubMed ID: 28884749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
    Magliacane G; Grassini G; Bartocci P; Francaviglia I; Dal Cin E; Barbieri G; Arrigoni G; Pecciarini L; Doglioni C; Cangi MG
    Oncotarget; 2015 Oct; 6(31):30592-603. PubMed ID: 26435479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing.
    Baum JE; Sung KJ; Tran H; Song W; Ginter PS
    Int J Surg Pathol; 2019 Jun; 27(4):441-445. PubMed ID: 30585117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
    Li HT; Lu YY; An YX; Wang X; Zhao QC
    Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
    Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
    Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
    Vranic S; Palazzo J; Sanati S; Florento E; Contreras E; Xiu J; Swensen J; Gatalica Z
    Clin Breast Cancer; 2019 Apr; 19(2):131-136. PubMed ID: 30268765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
    Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
    J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
    Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
    Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.